Survival Fraction Calculator
Calculate observed clonogenic survival fraction and predicted survival using the Linear-Quadratic (LQ) radiobiology model.
Calculation Method
Observed Clonogenic Inputs
LQ Model Inputs
Expert Guide to Survival Fraction Calculation
Survival fraction calculation is a foundational skill in radiobiology, radiation oncology research, and preclinical therapeutic development. In the most practical terms, a survival fraction (SF) tells you what portion of a cell population remains clonogenically viable after a treatment such as ionizing radiation, chemoradiation, or radiosensitizing drug exposure. A single value like SF2, which means survival fraction at 2 Gy, can summarize radiosensitivity and make comparison possible across cell lines, treatment conditions, and labs. For anyone performing dose-response experiments, a clean and reproducible SF workflow is non-negotiable.
The calculator above supports two standard pathways: an observed clonogenic method and a model-based LQ estimate. The observed method uses actual colony counts and control plating efficiency. The LQ approach predicts SF from dose and radiobiological constants alpha and beta. Used together, they allow both measurement and interpretation. This is particularly valuable if you want to test whether measured behavior aligns with expected radiation response biology.
What does survival fraction represent biologically?
In clonogenic assays, a surviving cell is not simply alive at the end of treatment. It must retain reproductive integrity and generate a macroscopic colony, traditionally defined as at least 50 cells. That means survival fraction reflects long-term proliferative capability, not short-term viability alone. This distinction matters because many cells can appear metabolically active after radiation yet still lose the ability to divide indefinitely. Clonogenic SF is therefore considered a gold-standard endpoint for radiation response.
- SF = 1.0 indicates no observed loss of clonogenic survival relative to normalized control.
- SF = 0.5 indicates 50% clonogenic survival.
- SF = 0.1 indicates 90% clonogenic loss.
Core formulas you should know
There are two formulas used most often in survival fraction work:
-
Observed clonogenic survival fraction
SF = colonies treated / (cells treated seeded × plating efficiency) -
Plating efficiency (PE)
PE = colonies control / cells control seeded -
Linear-Quadratic predicted survival
SF = exp( – (alpha × D + beta × D²) )
The LQ equation captures two damage components: a linear term (alpha) and a quadratic term (beta). At lower doses, alpha-driven effects dominate; at higher doses per fraction, beta contribution becomes more visible. In practical planning and interpretation, the alpha-to-beta ratio is used to describe tissue or tumor fractionation sensitivity.
Step-by-step protocol logic for reliable SF calculation
The most common source of SF error is not arithmetic. It is experimental inconsistency. A robust SF pipeline should include standardized seeding density, clear colony counting rules, enough technical replicates, and strict timing control. Below is a workflow used in many radiobiology labs:
- Plate cells in both control and treated groups at densities that avoid colony overlap.
- Allow attachment, then irradiate at defined doses with verified dosimetry.
- Incubate for a sufficient colony formation window, often 7 to 14 days depending on cell line.
- Fix and stain colonies using consistent stain concentration and wash steps.
- Count colonies manually with blinded duplicate counting or validated automated software.
- Compute control PE first, then normalize treated counts to PE.
- Plot dose versus log(SF) or SF directly and fit with the LQ model where appropriate.
If your PE is unexpectedly low in controls, do not ignore it. Low PE can reflect poor handling, contamination, plating stress, or inappropriate growth period. Since PE is part of the denominator in SF normalization, unstable control PE can distort every downstream result.
Representative radiobiology statistics used in interpretation
Experimental survival metrics vary by tumor type, molecular background, oxygenation status, and assay conditions. Still, some ranges are frequently reported in literature and useful for orientation during planning and QC.
| Tumor context | Commonly cited alpha-beta range (Gy) | Representative SF2 range | Interpretation trend |
|---|---|---|---|
| Prostate adenocarcinoma models | ~1.0 to 3.0 | ~0.45 to 0.70 | Higher fractionation sensitivity, often lower alpha-beta estimates |
| Breast cancer models | ~3.0 to 5.0 | ~0.35 to 0.65 | Moderate heterogeneity across subtypes |
| Head and neck squamous models | ~8.0 to 12.0 | ~0.40 to 0.75 | Often treated as more acutely responding tissue context |
| Glioma and GBM models | ~7.0 to 12.0 | ~0.55 to 0.85 | Many lines show relative radioresistance |
Values above are representative literature ranges used for educational benchmarking, not universal constants. Always use your own assay-derived parameters for formal analysis.
Clinical context: population survival statistics versus cellular survival fraction
A frequent confusion is mixing cell-level survival fraction with patient-level survival outcomes. These are related conceptually but not interchangeable endpoints. Cell SF reflects biological response under controlled lab conditions; clinical survival reflects many factors, including stage at diagnosis, systemic treatment, surgery, access to care, and comorbid conditions.
| Cancer site (U.S.) | Approximate 5-year relative survival | Clinical note |
|---|---|---|
| Prostate | ~97% | High overall long-term survival; treatment selection highly risk-stratified |
| Female breast | ~91% | Strong stage dependence; multimodality care drives outcomes |
| Colorectal | ~65% | Improving outcomes with screening and modern systemic therapy |
| Lung and bronchus | ~28% | Substantial variation by histology and stage; early detection matters |
Population survival percentages are aligned with U.S. SEER summary reporting and should be interpreted as broad epidemiologic indicators rather than trial-specific outcomes.
How to use the calculator above effectively
- Select Observed Clonogenic SF if you already have control and treated colony data.
- Select LQ Model Prediction when you need a modeled estimate from dose, alpha, and beta.
- Select Both to compare observed data against model prediction and evaluate agreement.
In combined mode, the tool reports plating efficiency, observed SF, LQ-predicted SF, and the relative percent difference. If your observed and predicted values diverge strongly, first check methodology before concluding biology is unusual. Common causes include counting threshold inconsistency, drift in dose calibration, or non-comparable control timing.
Frequent calculation and interpretation mistakes
- Using viability assay percentages as SF. MTT or ATP readouts are not direct substitutes for clonogenic survival.
- Ignoring control PE instability. Control PE must be valid and reproducible before treated data are trusted.
- Overfitting the LQ model with sparse points. Use enough dose points and replicates.
- Comparing SF values across labs without protocol harmonization. Medium, oxygen, and counting criteria matter.
- Assuming one alpha-beta fits all contexts. Cell line, microenvironment, and treatment combination can shift parameters.
Quality control checklist for publication-grade SF data
- Predefine colony size threshold and counting method.
- Use technical replicates per dose and biological replicates across runs.
- Confirm irradiator output and geometry routinely.
- Report confidence intervals for fitted alpha and beta.
- Include control PE distribution, not just mean PE.
- Document exclusion criteria before analysis.
For translational relevance, many groups also report hypoxia status, DNA repair genotype, or radiosensitizer condition alongside SF curves. These additions improve interpretability and reduce ambiguity when findings are compared with external datasets.
Authoritative references for deeper study
If you need validated background material and national-level statistics, start with these sources:
- National Cancer Institute (NCI): Radiation Therapy and Cancer
- SEER Stat Facts (U.S. population cancer statistics)
- CDC Radiation and Your Health
Bottom line
Survival fraction calculation is simple in formula, but high-stakes in execution. The strongest analyses combine excellent experimental controls with transparent normalization and model-based interpretation. Use observed clonogenic SF whenever possible, use LQ prediction to contextualize dose response, and never separate numbers from protocol quality. If you treat SF as both a mathematical and biological endpoint, your conclusions will be stronger, more reproducible, and more useful for translational decision-making.